Immunome Q1 EPS $(0.52) Beats $(0.81) Estimate
Portfolio Pulse from Benzinga Newsdesk
Immunome reported a Q1 EPS loss of $(0.52), surpassing the analyst consensus estimate of $(0.81) by 35.8%. However, this represents a 48.57% increase in losses compared to the same period last year, where the loss was $(0.35) per share.
May 13, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunome's Q1 EPS loss of $(0.52) exceeded expectations, indicating a potential positive short-term sentiment despite increased losses year-over-year.
Beating the EPS estimate typically generates positive sentiment among investors, potentially leading to a short-term increase in stock price. However, the increased loss year-over-year might temper optimism, making the overall impact moderately positive.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100